Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 14/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20754466 | 0.88 | TAS2R14 (0.49) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL20743179 | 0.88 | TAS2R14 (0.55) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL20757755 | 0.87 | TAS2R14 (0.49) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL20757427 | 0.84 | TAS2R14 (0.46) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL20757510 | 0.84 | MEN1 (0.49) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL20743206 | 0.83 | TAS2R14 (0.43) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL20757843 | 0.81 | TAS2R14 (0.50) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL20754557 | 0.78 | APLNR (0.46) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL20757374 | 0.78 | TAS2R14 (0.48) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL20758298 | 0.78 | TAS2R14 (0.47) | TAS2R14CXCR3PTGESTAS2R8APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | TAS2R14 828/4885CXCR3 2503/4885PTGES 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.